surufatinib + toripalimab + AG

This is a combination regimen consisting of surufatinib, toripalimab, and an unspecified agent abbreviated as "AG." Surufatinib is an oral small molecule multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R), thereby inhibiting angiogenesis and modulating the tumor microenvironment. Toripalimab is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The identity of "AG" in this context is unclear; no evidence was found for a standard oncology agent or defined drug with this abbreviation in combination with surufatinib and toripalimab. This combination has been studied primarily for advanced solid tumors, including neuroendocrine carcinoma, gastric/gastroesophageal adenocarcinoma, intrahepatic cholangiocarcinoma, and small cell lung cancer when combined with other agents such as etoposide/cisplatin or chemotherapy regimens[2][4][5][6]. The mechanism involves both antiangiogenic effects from surufatinib and immunomodulation via PD-1 blockade by toripalimab.